Home › Research › Lewy body dementia
Amyotrophic lateral sclerosis
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH.. Lancet (London, England), 2017-05-25
Topic: Brain proteins, microglia and lab models
Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases. Many different genes and pathophysiological processes contribute to the disease, and it will be necessary to understand this heterogeneity to find effective treatments. In this Seminar, we discuss clinical and diagnostic approaches as well as scientific advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategies.
Key findings
- Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord.
- This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases.
- Many different genes and pathophysiological processes contribute to the disease, and it will be necessary to understand this heterogeneity to find effective treatments.
- In this Seminar, we discuss clinical and diagnostic approaches as well as scientific advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategies.
Why it matters
This review describes amyotrophic lateral sclerosis as a progressive loss of motor neurons that shares features with frontotemporal dementia and involves many different genes and processes. It states that understanding this heterogeneity is necessary to find effective treatments, but reports no treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 59/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Lancet (London, England)) |
| Journal's citation record | 4 / 4 | The Lancet: journal h-index 1,205 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,301 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 118.3 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 6 / 6 | Cited 49.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 4 / 4 | Cited 394 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Leonard H. van den Berg: h-index 82 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | King's College London: institution h-index 1,348 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28552366) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/s0140-6736(17)31287-4
- PubMed: 28552366
- Original source →
- Free full text: Utrecht University Repository (Utrecht University) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., et al. (2017). Amyotrophic lateral sclerosis. Lancet (London, England). https://doi.org/10.1016/s0140-6736(17)31287-4
Vancouver
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet (London, England). 2017. doi:10.1016/s0140-6736(17)31287-4. PMID: 28552366.
BibTeX
@article{vanes2017-28552366,
author = {van Es, M. A. and Hardiman, O. and Chio, A. and Al-Chalabi, A. and Pasterkamp, R. J. and Veldink, J. H. and van den Berg, L. H.},
title = {{Amyotrophic lateral sclerosis}},
journal = {Lancet (London, England)},
year = {2017},
doi = {10.1016/s0140-6736(17)31287-4},
pmid = {28552366},
url = {https://doi.org/10.1016/s0140-6736(17)31287-4}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Lewy body dementia
Also in Lewy body dementia
39 studies in the library are filed under Lewy body dementia with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Lewy body dementia hub.